Impaired Memory in Subjects Receiving Opioid Agonist Treatment Who Also Abuse Benzodiazepines
Some studies have found impaired memory among subjects receiving opioid agonist treatment (OAT), but this may be partly due to baseline differences between subjects or the effects of other drugs, particularly benzodiazepines. This study tested memory function among Finnish subjects receiving methadone (n=13) or sublingual buprenorphine (n=15) who had concurrent benzodiazepine abuse or dependence and compared them with 15 healthy controls. Memory tests were conducted within 1–2 months of initiating OAT (T1) and repeated 6–9 months later (T2). Comparisons were adjusted for years of education and verbal IQ. Subjects on methadone received a mean daily dose of 73 mg at T1 and 126 mg at T2; those treated with buprenorphine received a mean daily dose of 17 mg at T1 and 23 mg at T2. All subjects receiving OAT also reported abusing a mean diazepam-equivalent dose of 25 mg daily at T1 and T2.
- Subjects in the OAT group performed significantly worse than controls on all memory tests except those related to memory consolidation.
- There was no significant difference in test results between subjects treated with methadone or buprenorphine.
- There was no significant difference in test results between T1 and T2.